Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR.

Cheol-Kyu Park,Hyung-Joo Oh,Young-Chul Kim,Yong-Hyub Kim,Sung-Ja Ahn,Won Gi Jeong,Jeong Yeop Lee,Jae Cheol Lee,Chang Min Choi,Wonjun Ji,Si Yeol Song,Juwhan Choi,Sung Yong Lee, Hakyung Kim,Shin Yup Lee,Jongmoo Park,Seong Hoon Yoon,Ji Hyeon Joo,In-Jae Oh

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2023）

引用 0|浏览7

暂无评分

摘要

Compared with the outcome of the PACIFIC trial, this real-world data demonstrated favorable survival benefits of DC after CRT in patients with unresectable stage III NSCLC. Blood-based biomarkers could predict higher-grade RP and irAEs before the initiation of DC.

查看译文

关键词

chemoradiotherapy,durvalumab,non-small cell lung cancer,real-world data

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要